This article examines the relationship between GLP-1 therapy and dyspnea, reviews clinical evidence, and provides guidance on managing respiratory symptoms during treatment
Wellstar Health System Bennett Cua, MD, FACC Bennett Cua, MD, FACC Mission Heritage Medical Group Jordan Lee Jordan Lee The Queen's Medical Center Vitaly Terushkin, M.D., FAAD, FACMS Vitaly Terushkin, M.D., FAAD, FACMS Vitaly Terushkin MD PLLC Otono Silva Otono Silva Interventional Orthopedics of Washington Shanedelle Norford, M.D., M.S., M.B.A Shanedelle Norford, M.D., M.S., M.B.A Pathnostics - A Diagnostics Solutions Company Find curated posts and insights for relevant topics all in one place
If you're on a weight - loss journey, these apps are about to become your new best friends
[2] [11] The American Diabetes Association recommends specific GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high cardiovascular risk